Lipid Profile Features and Their Associations With Disease Severity and Mortality in Patients With COVID-19

Background: Emerging studies have described and analyzed epidemiological, clinical, laboratory, and radiological features of COVID-19 patients. Yet, scarce information is available regarding the association of lipid profile features and disease severity and mortality.Methods: We conducted a prospect...

Full description

Bibliographic Details
Main Authors: Jia Teng Sun, Zhongli Chen, Peng Nie, Heng Ge, Long Shen, Fan Yang, Xiao Long Qu, Xiao Ying Ying, Yong Zhou, Wei Wang, Min Zhang, Jun Pu
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2020.584987/full
id doaj-82636c55a49b4fba9626adea2dd50a9c
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Jia Teng Sun
Jia Teng Sun
Zhongli Chen
Peng Nie
Peng Nie
Heng Ge
Heng Ge
Long Shen
Long Shen
Fan Yang
Fan Yang
Xiao Long Qu
Xiao Long Qu
Xiao Ying Ying
Xiao Ying Ying
Yong Zhou
Yong Zhou
Wei Wang
Wei Wang
Min Zhang
Min Zhang
Jun Pu
spellingShingle Jia Teng Sun
Jia Teng Sun
Zhongli Chen
Peng Nie
Peng Nie
Heng Ge
Heng Ge
Long Shen
Long Shen
Fan Yang
Fan Yang
Xiao Long Qu
Xiao Long Qu
Xiao Ying Ying
Xiao Ying Ying
Yong Zhou
Yong Zhou
Wei Wang
Wei Wang
Min Zhang
Min Zhang
Jun Pu
Lipid Profile Features and Their Associations With Disease Severity and Mortality in Patients With COVID-19
Frontiers in Cardiovascular Medicine
HDL-C
apoA-1
inflammation
lipid
COVID-19
author_facet Jia Teng Sun
Jia Teng Sun
Zhongli Chen
Peng Nie
Peng Nie
Heng Ge
Heng Ge
Long Shen
Long Shen
Fan Yang
Fan Yang
Xiao Long Qu
Xiao Long Qu
Xiao Ying Ying
Xiao Ying Ying
Yong Zhou
Yong Zhou
Wei Wang
Wei Wang
Min Zhang
Min Zhang
Jun Pu
author_sort Jia Teng Sun
title Lipid Profile Features and Their Associations With Disease Severity and Mortality in Patients With COVID-19
title_short Lipid Profile Features and Their Associations With Disease Severity and Mortality in Patients With COVID-19
title_full Lipid Profile Features and Their Associations With Disease Severity and Mortality in Patients With COVID-19
title_fullStr Lipid Profile Features and Their Associations With Disease Severity and Mortality in Patients With COVID-19
title_full_unstemmed Lipid Profile Features and Their Associations With Disease Severity and Mortality in Patients With COVID-19
title_sort lipid profile features and their associations with disease severity and mortality in patients with covid-19
publisher Frontiers Media S.A.
series Frontiers in Cardiovascular Medicine
issn 2297-055X
publishDate 2020-12-01
description Background: Emerging studies have described and analyzed epidemiological, clinical, laboratory, and radiological features of COVID-19 patients. Yet, scarce information is available regarding the association of lipid profile features and disease severity and mortality.Methods: We conducted a prospective observational cohort study to investigate lipid profile features in patients with COVID-19. From 9 February to 4 April 2020, a total of 99 patients (31 critically ill and 20 severely ill) with confirmed COVID-19 were included in the study. Dynamic alterations in lipid profiles were recorded and tracked. Outcomes were followed up until 4 April 2020.Results: We found that high-density lipoprotein-cholesterol (HDL-C) and apolipoprotein A-1 (apoA-1) levels were significantly lower in the severe disease group, with mortality cases showing the lowest levels (p < 0.0001). Furthermore, HDL-C and apoA-1 levels were independently associated with disease severity (apoA-1: odds ratio (OR): 0.651, 95% confidence interval (CI): 0.456–0.929, p = 0.018; HDL-C: OR: 0.643, 95% CI: 0.456–0.906, p = 0.012). For predicting disease severity, the areas under the receiver operating characteristic curves (AUCs) of HDL-C and apoA-1 levels at admission were 0.78 (95% CI, 0.70–0.85) and 0.85 (95% CI, 0.76–0.91), respectively. For in-hospital deaths, HDL-C and apoA-1 levels demonstrated similar discrimination ability, with AUCs of 0.75 (95% CI, 0.61–0.88) and 0.74 (95% CI, 0.61–0.88), respectively. Moreover, patients with lower serum concentrations of apoA-1 (<0.95 g/L) or HDL-C (<0.84 mmol/l) had higher mortality rates during hospitalization (log-rank p < 0.001). Notably, levels of apoA-1 and HDL-C were inversely proportional to disease severity. The survivors of severe cases showed significant recovery of apoA-1 levels at the end of hospitalization (vs. midterm apoA-1 levels, p = 0.02), whereas the mortality cases demonstrated continuously lower apoA-1 levels throughout hospitalization. Correlation analysis revealed that apoA-1 and HDL-C levels were negatively correlated with both admission levels and highest concentrations of C-reactive protein and interleukin-6.Conclusions: Severely ill COVID-19 patients featured low HDL-C and apoA-1 levels, which were strongly correlated with inflammatory states. Thus, low apoA-1 and HDL-C levels may be promising predictors for severe disease and in-hospital mortality in patients suffering from COVID-19.
topic HDL-C
apoA-1
inflammation
lipid
COVID-19
url https://www.frontiersin.org/articles/10.3389/fcvm.2020.584987/full
work_keys_str_mv AT jiatengsun lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
AT jiatengsun lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
AT zhonglichen lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
AT pengnie lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
AT pengnie lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
AT hengge lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
AT hengge lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
AT longshen lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
AT longshen lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
AT fanyang lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
AT fanyang lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
AT xiaolongqu lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
AT xiaolongqu lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
AT xiaoyingying lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
AT xiaoyingying lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
AT yongzhou lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
AT yongzhou lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
AT weiwang lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
AT weiwang lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
AT minzhang lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
AT minzhang lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
AT junpu lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19
_version_ 1724390861286932480
spelling doaj-82636c55a49b4fba9626adea2dd50a9c2020-12-08T08:34:56ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2020-12-01710.3389/fcvm.2020.584987584987Lipid Profile Features and Their Associations With Disease Severity and Mortality in Patients With COVID-19Jia Teng Sun0Jia Teng Sun1Zhongli Chen2Peng Nie3Peng Nie4Heng Ge5Heng Ge6Long Shen7Long Shen8Fan Yang9Fan Yang10Xiao Long Qu11Xiao Long Qu12Xiao Ying Ying13Xiao Ying Ying14Yong Zhou15Yong Zhou16Wei Wang17Wei Wang18Min Zhang19Min Zhang20Jun Pu21Division of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Pulmonary and Critical Care Medicine, Leishenshan Hospital, Wuhan, ChinaInstitute of Cardiovascular Disease, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Pulmonary and Critical Care Medicine, Leishenshan Hospital, Wuhan, ChinaDivision of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Pulmonary and Critical Care Medicine, Leishenshan Hospital, Wuhan, ChinaDivision of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Pulmonary and Critical Care Medicine, Leishenshan Hospital, Wuhan, ChinaDivision of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Pulmonary and Critical Care Medicine, Leishenshan Hospital, Wuhan, ChinaDivision of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Pulmonary and Critical Care Medicine, Leishenshan Hospital, Wuhan, ChinaDivision of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Pulmonary and Critical Care Medicine, Leishenshan Hospital, Wuhan, ChinaDivision of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Pulmonary and Critical Care Medicine, Leishenshan Hospital, Wuhan, ChinaDivision of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Pulmonary and Critical Care Medicine, Leishenshan Hospital, Wuhan, ChinaDivision of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Pulmonary and Critical Care Medicine, Leishenshan Hospital, Wuhan, ChinaDivision of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaBackground: Emerging studies have described and analyzed epidemiological, clinical, laboratory, and radiological features of COVID-19 patients. Yet, scarce information is available regarding the association of lipid profile features and disease severity and mortality.Methods: We conducted a prospective observational cohort study to investigate lipid profile features in patients with COVID-19. From 9 February to 4 April 2020, a total of 99 patients (31 critically ill and 20 severely ill) with confirmed COVID-19 were included in the study. Dynamic alterations in lipid profiles were recorded and tracked. Outcomes were followed up until 4 April 2020.Results: We found that high-density lipoprotein-cholesterol (HDL-C) and apolipoprotein A-1 (apoA-1) levels were significantly lower in the severe disease group, with mortality cases showing the lowest levels (p < 0.0001). Furthermore, HDL-C and apoA-1 levels were independently associated with disease severity (apoA-1: odds ratio (OR): 0.651, 95% confidence interval (CI): 0.456–0.929, p = 0.018; HDL-C: OR: 0.643, 95% CI: 0.456–0.906, p = 0.012). For predicting disease severity, the areas under the receiver operating characteristic curves (AUCs) of HDL-C and apoA-1 levels at admission were 0.78 (95% CI, 0.70–0.85) and 0.85 (95% CI, 0.76–0.91), respectively. For in-hospital deaths, HDL-C and apoA-1 levels demonstrated similar discrimination ability, with AUCs of 0.75 (95% CI, 0.61–0.88) and 0.74 (95% CI, 0.61–0.88), respectively. Moreover, patients with lower serum concentrations of apoA-1 (<0.95 g/L) or HDL-C (<0.84 mmol/l) had higher mortality rates during hospitalization (log-rank p < 0.001). Notably, levels of apoA-1 and HDL-C were inversely proportional to disease severity. The survivors of severe cases showed significant recovery of apoA-1 levels at the end of hospitalization (vs. midterm apoA-1 levels, p = 0.02), whereas the mortality cases demonstrated continuously lower apoA-1 levels throughout hospitalization. Correlation analysis revealed that apoA-1 and HDL-C levels were negatively correlated with both admission levels and highest concentrations of C-reactive protein and interleukin-6.Conclusions: Severely ill COVID-19 patients featured low HDL-C and apoA-1 levels, which were strongly correlated with inflammatory states. Thus, low apoA-1 and HDL-C levels may be promising predictors for severe disease and in-hospital mortality in patients suffering from COVID-19.https://www.frontiersin.org/articles/10.3389/fcvm.2020.584987/fullHDL-CapoA-1inflammationlipidCOVID-19